
|Articles|November 2, 2006
Injectable enzyme appears effective in treating Peyronie's disease
An investigational injectable enzyme known as AA4500 appears to be effective and generally well tolerated in treating patients with Peyronie's disease, according to data from two phase II open-label trials presented at the recent AUA Western Section annual meeting in Maui, HI.
Advertisement
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
3
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5










